Cancer being one of the most dreadful diseases and inflammation in cancer is one of the emerged Hallmarks of cancer. Discovering new drugs with minimal side effects plays a vital role in drug development process for the treatment of cancer. As an approach antitumor hybrid of "Benzophenone coupled with diamide analog "BT009K" or N-(2-{2-[4-(4-bromo-benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] was screened against different cell lines. Cytotoxic effect was found to be effective against EAC with prolonged effect. The in-vivo antitumor effect was observed in EAC ascites tumor model system with reduced peritoneal neovascularisation. Further histological examination with endothelial marker CD31 confirmed the angioregressive effect of BT009K. The results were additionally confirmed in a non-tumorigenic model like CAM and rat corneal angiogenesis assay indicating reduced microvessel density count by BT009K. Further BT009K induces the anti-invasive effect in EAC cells in-vitro which could be further developed into therapeutic potential.
INTRODUCTION
Cancer is defined as the interplay between cell intrinsic and extrinsic process due to the instability in the genome, abnormality in the proliferation of cells, inaccuracy in the stromal environment and atypical differentiation amongst epithelial and mesenchymal status (Eran et al., 2013) . The development of cancer can be attributed with six vital possessions that cells undergo evasion of apoptosis, uncontrolled angiogenesis, negligence to anti-proliferative signals, unconstrained replicative potential, tissue invasion followed by metastasis (Hanahan and Weinberg, 2000) . Three phases take place in the development of cancer initiation, promotion, and progression. Initiation is started through genomic instability in cancer cells promoting for tumor development endorsed by the survival and clonal expansion and followed by significant growth in tumor size and metastasis of tumor cells (Kinzler and Vogelstein, 1996) .
Inflammation, the physiological reaction of the body due to the mutilation of tissue damage instigated through microbes, wounds, chemical irritation (Philip et al., 2004) . Inflammation categorized into acute and chronic if the healing of inflammation does not take place it progress from acute to chronic inflammation resulting in recruitment of lymphocytes, leukocytes and various inflammatory cells at the site of the inflamed site. Further chronic inflammation mediates to the formation of the tumor by making a suitable environment for the cancer cells (Coussens and Werb, 2002; Nathan, 2002) . Inflammation during tumor progression induces the angiogenic mediators triggering the angiogenesis (Pollard JW, 2006) . Angiogenesis is known as restoration and progression of the new vascular system from the existing matured vasculature to form branching network (Carmeliet, 2005) .
Extensive angiogenesis plays a major role in tumor formation thus chronic inflammation and angiogenesis play synergetic effect in cancer. So Blockade of this combination results in the reduction of a tumor, in conquest to find a potent inhibitor of inflammatory angiogenesis.
Benzophenone molecules bring us hope in this conquest. Benzophenone molecules are known for their potency against a tumor (Prabhakar et al., 2006) with minimal effect on normal cells. As an approach in designing of the compound, we have conjugated Diamide to benzophenone and reported "N-(2-{2-[4-(4-bromobenzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] acetamide (BT0009K)" (Fig. 1a) has potent antitumor efficacy against multiple cancer cell lines with regression of angiogenesis (Zabiulla et al., 2016) . In the current detailed investigation of BT009K has been carried out to infer that it effectively reduces inflammation-induced angiogenesis in both tumorigenic and non-tumorigenic model system. 
MATERIALS AND METHOD

In-vitro assays
Cell culture and maintenance
Ehrlich Ascites-E (EAC), Dalton's Ascites Lymphoma (DLA), Breast adenocarcinoma (MCF-7), Lung adenocarcinoma (A549), Hepatocellular carcinoma (HUH-7, HepG2), human melanoma (A375), mouse melanoma (B16F10)cell lines were procured from NCCS Pune. Cells were cultured using DMEM or RPMI media (Gibco-Invitrogen, USA), with 10% FBS (Invitrogen, USA), suitable antibiotics and antimitotic (Sigma Aldrich, USA), in a humidified incubator at 37 o C with the supply of 5% CO2.
Lactate dehydrogenase assay
The cytotoxic effect of BT009K was assessed through LDH release assay screened against EAC, DLA, Huh-7, Hepg2, B16F10, A375, A549, and MCF-7. Cells were treated with or without BT009K in different concentration (0, 5, 10, 25, 50 , and 100 µm) for 48 hrs of incubation as stated previously (Ranganath et al., 2013) . The percentage of LDH released to the media was directly proportional to the percentage of dead cells.
Clonogenic assay
Anti-neoplastic effect of BT009K against EAC cell proliferation in-vitro (Franken et al., 2006) was carried out accordingly. In brief, EAC cells were cultured in eight-well plate in-vitro and exposed with BT009K for 6 hrs and washed with fresh medium. After culturing for 12 days 12 days cells were fixed with methanol and stained with crystal violet and colonies were counted and photographed.
Migration assay
EAC cells were cultured in-vitro, scratched and treated with or without BT009K for 48 hrs. Cells were fixed with methanol, stained in crystal violet and images were photographed at 10X resolution. Differences in the percentage of cell migration in treated and control were analyzed (Cory, 2011) .
Non tumorigenic assays
Chorioallontoic membrane (CAM) assay
Anti-angiogenic effect of BT009K was analyzed through rVEGF165 induced in-vivo CAM assay followed by treatment with BT009K within 8 days of fertilized eggs as described earlier (Prabhakar et al., 2006) . Changes in the microvessel density (MVD) count was observed and photographed.
Corneal inflammatory angiogenesis assay
Anti-inflammatory angiogenesis effect of BT009K was assessed through rat corneal inflammatory angiogenesis assay by anesthetizing the animal with ketamine and xylazine. Followed by placing the sterile filter paper discs pre-dipped in 1 M NaOH (alkaline solution) and placing it on the eye for 30 seconds. The eyes were washed immediately with Phosphate buffer saline for inducing inflammatory angiogenesis. The recombinant VEGF165 was used to enhance the angiogenesis in the cornea in presence or absence of BT009K (0, 10, and 20 µm). After 4 days developed MVD was observed in the cornea of the rats and quantified. The cornea was dissected and processed for histological examination for vascular modulation (Prabhu et al., 2017) .
Tumorigenic assays
Animal models and ethics
Male Swiss albino mice weighing 25-28 g of 35-45 days old were used for this study. Each group consisted of 10 mice caged in polyacrylic cages with a supply of standard food and water. The Institutional animal ethical committee (IAEC) certificate was obtained from SJM College of pharmacy, Chitradurga, India, in accordance with the CPCSEA guidelines for laboratory animal facility (SJMCP/IAEC/07/2015-16).
Tumor models and treatment
Effect of BT009K in in-vivo tumor model system was checked in EAC ascites model system. In brief, Ehrlich ascites carcinoma cells (5 × 10 6 cells) were cultured and transplanted into three groups of male Swiss albino mice. Each group consists of n = 10 animals. After the development of a tumor, BT009K was treated at two different concentration 50 mg and 75 mg/kg body weight along with appropriate vehicle control. Treatment was given on every alternate day after tumor establishment. On the last day, (10th day) of tumor growth mice was sacrificed and different tumor parameters like packed cell volume, ascites volume, tumor growth, and survival were assessed (Vijay Avin et al., 2014) .
Peritoneal angiogenesis
The density of Microvessel formation in the peritoneum region of a tumor-bearing mice treated with BT009K (50, 75 mgkg body weight) was assessed as reported earlier (Weidner et al., 1991) .
Immunohistochemical (IHC) analysis
Peritoneum from the control and BT009K treated mice were processed for immunostaining with Anti-CD31 antibody for MVD evaluation along with H&E stained counter slides as reported earlier (Prabhu et al., 2017) . The slides were observed in the light microscope and the changes in the intensity of the antibody staining were evaluated.
RESULTS AND DISCUSSION
BT009K induces cytotoxicity against EAC cells
Lactate dehydrogenase (LDH) release assay system is one of the gold standard assays to study the cytotoxic ability of compound where an increase in the LDH enzyme in the media is directly proportional to the number of lysed cells (Chan et al., 2013) . BT009K was screened against EAC, DLA, A549, Huh-7, HepG2, MCF-7, A375, and B16F10. Cells were incubated for 48 hrs with BT009K (0, 5, 10, 25, 50, and 100 µm). BT009K (Fig. 1a) showed a significant cytotoxic effect against EAC with an IC50 value of 3.9 μm. But moderate activity was reported against A549 and MCF-7 and DLA cell lines with 24, 23, and 23 um, respectively. No significant activity was observed in Huh-7, Hepg2, A375, and B16F10 cell lines (Fig. 1b) inferring the specificity of BT009K against EAC cells. Each tumor has their own drug response and long-term cytotoxicity of drugs varies for different tumor cells. Each tumor has individual scale against different compounds (Robert, 1991) . To check the longterm ability of BT009K on tumor cells, a clonogenic assay was performed which is one of the foremost assay systems to evaluate the colony forming ability. The BT009K induces Longterm cytotoxic effect against EAC cells with the decreased number of colonies inferring the prolonged cytotoxic effect of the compound on EAC cells in a dose-dependent manner. Around 50% decrease in 10 μm concentration and 80% decrease in 20 μm concentration as compared to the untreated cells were noticed (Fig. 1c) .
Cell migration is one of the fundamental pathological and physiological process involved during inflammation, cancer and wound healing conditions. During the process of cell migration, different proteins and enzymes like VEGF, MMP2, 9 play a vital role. Migration of tumor cells is the last stage in cancer progression and compound inhibiting the migration of tumor cells is vital for regression of a tumor, Migration assay is the suitable type of assay to assess the capability of compounds against tumor cell migration (Hulkower and Herber 2011). The BT009K regressed the migration of tumor cells as observed in migration assay in a concentration-dependent manner compared to the control (Fig.  1d) . The result implies BT009K is a potent cytotoxic molecule with anti-invasive behavior. 
BT009K antiangiogenic molecule in the non-tumorigenic model system
Non-tumorigenic models are often used to check the effect of compounds. Chorioallantoic membrane assay is one of the supportive angiogenic assay systems were rVEGF165 induced neovascularisation is formed (Prabhakar et al., 2006) . Newly developed vascularisation was reduced in BT009K treated egg CAM compared to the untreated in a dose-dependent manner (Fig. 2a) . Further, the effect of BT009K was checked in inflammation-induced angiogenesis model viz Rat corneal angiogenesis. In this model, alkali burn induces local inflammation in the cornea and which causes extensive inflammation of sprouting of a blood vessel (Zhou et al., 2010) . The BT009K effectively reduces the MVD in corneal region induced by inflammation in a concentrationdependent manner. About ~50% decrease in MVD density in 10 µm concentration and in 20 µm concentration was nearly to the normal (Fig. 2b) .
BT009K regresses ascites a tumor in an in-vivo model
In-vivo ascites tumour model is one of the best model systems to study inflammatory mediated angiogenesis were tumour cells are cultured in the peritoneum region of mice, tumour cells recruit various inflammatory cells and thereby inducing angiogenesis by enhancing the pro-angiogenic signalling molecules and this results in extensive formation of neovascularization and leading to the development of a tumour (Vijay Avin et al., 2014) . The in-vivo cytotoxic effect of BT009K was confirmed by in-vivo culturing EAC cells (5 × 10 6 cells) in the peritoneum region of healthy Swiss albino mice weighing about 25-28 g, after the onset of a tumor in mice BT009K was treated to mice with two different concentrations, i.e., 50 mg and 75mg/Kg bwt. Treatment was given for three doses on alternate days and resulted in reduced tumor growth in a dose-dependent manner compared to the untreated (Fig. 3a) . The findings were concurrent with other tumor growth parameters like body weight (Fig. 3d) , ascites secretion (Fig. 3b) and tumor cell counts (Fig. 3c ). Treatment with BT009K treated also increases with survival time than compared with untreated animals (Fig. 3e) .
BT009K reduces neovascularisation in peritoneum region
The ascites tumor model system helps in generating stroma when tumor cells are implanted in the peritoneum region thereby inducing neovascularization in peritoneum region (Janice et al., 1995) . Neovascularisation during cancer condition benefits a tumor by supplying essential nutrients and growth factors for tumor cells, endothelial cells express CD31 as cell surface marker during cancer condition due to extensive vascularisation expression of CD31 is also increased (Weidner et al., 1991) . EAC bearing mice are the best reliable model to study neovascularisation in the peritoneum region of mice. The peritoneum of BT009K treated mice showed reduced MVD as seen visibly in the peritoneal lining (Fig. 4a) . Further histological examination confirmed the reduced MVD count both H&E stain (Fig.   4b ) as well as CD31 immunostain (Fig. 4c) . 
CONCLUSION
Unregulated inflammation turns from acute stage to chronic stage leading to malignancy. Inflammation and angiogenesis both play a major role in the development of a tumor. Benzophenones are known for highly target specific compounds. As in the path of development target specific drugs, we focused on the coupling of Diamide group to the Benzophenone, which is one of the basic approaches to develop an effective drug, BT009K. The BT009K was screened against multiple cell lines using LDH release assay to evaluate the cytotoxic nature which was found to be more effective in EAC with 3.9 μM than any other cell lines along with prolonged cytotoxic effect. Down the line, BT009K compound implied antiangiogenic effect both in non-tumorigenic and this non-tumorigenic model both in-vitro and in-vivo. Considering the above results BT009K can be further developed as target specific drug in inflammatory angiogenesis disorders.
